Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Genetic Vaccines and Therapy
Published in: Genetic Vaccines and Therapy 1/2005

Open Access 01-12-2005 | Research

Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax

Authors: Stuart D Perkins, Helen C Flick-Smith, Helen S Garmory, Angela E Essex-Lopresti, Freda K Stevenson, Robert J Phillpotts

Published in: Genetic Vaccines and Therapy | Issue 1/2005

Login to get access

Abstract

Background

Previously, antigens expressed from DNA vaccines have been fused to the VP22 protein from Herpes Simplex Virus type I in order to improve efficacy. However, the immune enhancing mechanism of VP22 is poorly understood and initial suggestions that VP22 can mediate intercellular spread have been questioned. Despite this, fusion of VP22 to antigens expressed from DNA vaccines has improved immune responses, particularly to non-secreted antigens.

Methods

In this study, we fused the gene for the VP22 protein to the gene for Protective Antigen (PA) from Bacillus anthracis, the causative agent of anthrax. Protective immunity against infection with B. anthracis is almost entirely based on a response to PA and we have generated two constructs, where VP22 is fused to either the N- or the C-terminus of the 63 kDa protease-cleaved fragment of PA (PA63).

Results

Following gene gun immunisation of A/J mice with these constructs, we observed no improvement in the anti-PA antibody response generated. Following an intraperitoneal challenge with 70 50% lethal doses of B. anthracis strain STI spores, no difference in protection was evident in groups immunised with the DNA vaccine expressing PA63 and the DNA vaccines expressing fusion proteins of PA63 with VP22.

Conclusion

VP22 fusion does not improve the protection of A/J mice against live spore challenge following immunisation of DNA vaccines expressing PA63.
Appendix
Available only for authorised users
Literature
1.
Leifert JA, Whitton JL: "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms. Mol Ther. 2003, 8: 13-20. 10.1016/S1525-0016(03)00151-5.CrossRefPubMed
2.
Elliott G, O'Hare P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 1997, 88: 223-233. 10.1016/S0092-8674(00)81843-7.CrossRefPubMed
3.
Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI, O'Hare P: Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther. 1999, 6: 12-21. 10.1038/sj.gt.3300838.CrossRefPubMed
4.
Phelan A, Elliott G, O'Hare P: Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol. 1998, 16: 440-443. 10.1038/nbt0598-440.CrossRefPubMed
5.
Wills KN, Atencio IA, Avanzini JB, Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT, Wen SF, Ralston RO, Johnson DE: Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus. J Virol. 2001, 75: 8733-8741. 10.1128/JVI.75.18.8733-8741.2001.PubMedCentralCrossRefPubMed
6.
Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, Drobek S, Galanski M, Kuhnel F, Manns M, Kubicka S: Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology. 2002, 123: 608-618. 10.1053/gast.2002.34756.CrossRefPubMed
7.
Lai Z, Han I, Zirzow G, Brady RO, Reiser J: Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors. Proc Natl Acad Sci U S A. 2000, 97: 11297-11302. 10.1073/pnas.97.21.11297.PubMedCentralCrossRefPubMed
8.
Cheng WF, Hung CH, Chai CY, Hsu KF, He L, Ling M, Wu TC: Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol. 2001, 75: 2368-2376. 10.1128/JVI.75.5.2368-2376.2001.PubMedCentralCrossRefPubMed
9.
Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, Slater LA, Ling M, Wu TC: Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22--Antigen Fusion. Hum Gene Ther. 2002, 13: 553-568. 10.1089/10430340252809847.CrossRefPubMed
10.
Lundberg M, Johansson M: Is VP22 nuclear homing an artifact?. Nat Biotechnol. 2001, 19: 713-714. 10.1038/90741.CrossRefPubMed
11.
Elliott G, O'Hare P: Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 1999, 6: 149-151. 10.1038/sj.gt.3300850.CrossRefPubMed
12.
Falnes PO, Wesche J, Olsnes S: Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry. 2001, 40: 4349-4358. 10.1021/bi002443l.CrossRefPubMed
13.
McBride BW, Mogg A, Telfer JL, Lever MS, Miller J, Turnbull PC, Baillie L: Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine. 1998, 16: 810-817. 10.1016/S0264-410X(97)00268-5.CrossRefPubMed
14.
Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GWJ, Gibbs PH, Friedlander AM: Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 1998, 16: 1141-1148. 10.1016/S0264-410X(98)80112-6.CrossRefPubMed
15.
Mikesell P, Ivins BE, Ristroph JD, Dreier TM: Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun. 1983, 39: 371-376.PubMedCentralPubMed
16.
Klimpel KR, Molloy SS, Thomas G, Leppla SH: Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A. 1992, 89: 10277-10281.PubMedCentralCrossRefPubMed
17.
Friedlander AM: Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. 1986, 261: 7123-7126.PubMed
18.
Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC: Crystal structure of the anthrax toxin protective antigen. Nature. 1997, 385: 833-838. 10.1038/385833a0.CrossRefPubMed
19.
Gu ML, Leppla SH, Klinman DM: Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine. 1999, 17: 340-344. 10.1016/S0264-410X(98)00210-2.CrossRefPubMed
20.
Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR: Protection against anthrax lethal toxin challenge by genetic immunisation with a plasmid encoding the lethal factor protein. Infect Immun. 2001, 4509-4515. 10.1128/IAI.69.7.4509-4515.2001.
21.
Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C: Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003, 21: 4071-4080. 10.1016/S0264-410X(03)00362-1.CrossRefPubMed
22.
Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P: A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci U S A. 2004, 101: 13601-13606. 10.1073/pnas.0405557101.PubMedCentralCrossRefPubMed
23.
Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M: Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination. Virology. 2002, 294: 47-59. 10.1006/viro.2001.1321.CrossRefPubMed
24.
Oliveira SC, Harms JS, Afonso RR, Splitter GA: A genetic immunization adjuvant system based on BVP22-antigen fusion. Hum Gene Ther. 2001, 12: 1353-1359. 10.1089/104303401750271002.CrossRefPubMed
25.
Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, Wu TC: Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol. 2001, 166: 5733-5740.CrossRefPubMed
26.
Perkins SD, Hartley MG, Lukaszewski RA, Phillpotts RJ, Stevenson FK, Bennett AM: VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine. 2005, 23: 1931-1940. 10.1016/j.vaccine.2004.10.033.CrossRefPubMed
27.
Kueltzo LA, Normand N, O'Hare P, Middaugh CR: Conformational lability of herpesvirus protein VP22. J Biol Chem. 2000, 275: 33213-33221. 10.1074/jbc.M002476200.CrossRefPubMed
28.
Hobert O: PCR fusion-based approach to create reporter gene constructs for expression analysis in transgenic C. elegans. Biotechniques. 2002, 32: 728-730.PubMed
29.
Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED: Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus. Vaccine. 1999, 18: 588-596. 10.1016/S0264-410X(99)00317-5.CrossRefPubMed
30.
Beedham RJ, Turnbull PC, Williamson ED: Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine. 2001, 19: 4409-4416. 10.1016/S0264-410X(01)00197-9.CrossRefPubMed
31.
Lundberg M, Johansson M: Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun. 2002, 291: 367-371. 10.1006/bbrc.2002.6450.CrossRefPubMed
32.
Lundberg M, Wikstrom S, Johansson M: Cell surface adherence and endocytosis of protein transduction domains. Mol Ther. 2003, 8: 143-150. 10.1016/S1525-0016(03)00135-7.CrossRefPubMed
33.
Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC: Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen. J Virol. 2002, 76: 2676-2682. 10.1128/JVI.76.6.2676-2682.2002.PubMedCentralCrossRefPubMed
34.
Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, Boyd DA, Wu TC: Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther. 2004, 15: 167-177. 10.1089/104303404772679977.CrossRefPubMed
35.
Bennett AM, Perkins SD, Holley JL: DNA vaccination protects against botulinum neurotoxin type F. Vaccine. 2003, 21: 3110-3117. 10.1016/S0264-410X(03)00260-3.CrossRefPubMed
36.
You Z, Huang X, Hester J, Toh HC, Chen SY: Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 2001, 61: 3704-3711.PubMed
37.
Rice J, King CA, Spellerberg MB, Fairweather N, Stevenson FK: Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine. 1999, 17: 3030-3038. 10.1016/S0264-410X(99)00171-1.CrossRefPubMed
38.
King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med. 1998, 4: 1281-1286. 10.1038/3266.CrossRefPubMed
Metadata
Title
Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax
Authors
Stuart D Perkins
Helen C Flick-Smith
Helen S Garmory
Angela E Essex-Lopresti
Freda K Stevenson
Robert J Phillpotts
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Genetic Vaccines and Therapy / Issue 1/2005
Electronic ISSN: 1479-0556
DOI
https://doi.org/10.1186/1479-0556-3-3

Other articles of this Issue 1/2005

Genetic Vaccines and Therapy 1/2005 Go to the issue

Research

A trial of somatic gene targeting in vivo with an adenovirus vector

Research

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas

Research

A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses

Methodology

Electroporation by nucleofector is the best nonviral transfection technique in human endothelial and smooth muscle cells

Research

Human cytomegalovirus plasmid-based amplicon vector system for gene therapy

Research

Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines